NASDAQ:ANAB - AnaptysBio Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$77.90 -4.77 (-5.77 %)
(As of 05/27/2018 04:00 PM ET)
Previous Close$77.90
Today's Range$75.00 - $82.17
52-Week Range$18.15 - $134.00
Volume644,898 shs
Average Volume295,986 shs
Market Capitalization$1.83 billion
P/E Ratio-51.25
Dividend YieldN/A
Beta3.51

About AnaptysBio (NASDAQ:ANAB)

AnaptysBio logoAnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize monospecific antibody product candidates targeting TIM-3 (TSR-022), LAG-3 (TSR-033), and PD-1 (TSR-042), as well as a bispecific antibody product candidate targeting PD-1 and LAG-3; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 agonist antibody (CC-90006) that is in Phase 1 trial. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.

Receive ANAB News and Ratings via Email

Sign-up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ANAB
CUSIPN/A
Phone858-362-6295

Debt

Debt-to-Equity Ratio0.02
Current Ratio17.57
Quick Ratio17.57

Price-To-Earnings

Trailing P/E Ratio-51.25
Forward P/E Ratio-25.63
P/E GrowthN/A

Sales & Book Value

Annual Sales$10 million
Price / Sales183.07
Cash FlowN/A
Price / CashN/A
Book Value$12.53 per share
Price / Book6.22

Profitability

EPS (Most Recent Fiscal Year)($1.52)
Net Income$-30,070,000.00
Net MarginsN/A
Return on Equity-16.60%
Return on Assets-15.05%

Miscellaneous

Employees60
Outstanding Shares23,500,000

AnaptysBio (NASDAQ:ANAB) Frequently Asked Questions

What is AnaptysBio's stock symbol?

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

How were AnaptysBio's earnings last quarter?

AnaptysBio Inc (NASDAQ:ANAB) announced its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.63) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.19. During the same quarter in the prior year, the firm earned ($0.75) earnings per share. View AnaptysBio's Earnings History.

What price target have analysts set for ANAB?

8 brokerages have issued 1-year target prices for AnaptysBio's stock. Their predictions range from $40.00 to $180.00. On average, they expect AnaptysBio's share price to reach $138.6250 in the next twelve months. View Analyst Ratings for AnaptysBio.

Are investors shorting AnaptysBio?

AnaptysBio saw a increase in short interest during the month of April. As of April 13th, there was short interest totalling 2,515,518 shares, an increase of 43.4% from the March 30th total of 1,754,800 shares. Based on an average daily volume of 578,333 shares, the short-interest ratio is currently 4.3 days. Approximately 15.1% of the shares of the company are short sold.

Who are some of AnaptysBio's key competitors?

Who are AnaptysBio's key executives?

AnaptysBio's management team includes the folowing people:
  • Mr. Hamza Suria, Pres, CEO & Director (Age 42)
  • Mr. Dominic G. Piscitelli M.B.A., CPA, Chief Financial Officer (Age 43)
  • Prof. Marco Londei, Chief Medical Officer (Age 61)
  • Mr. Bob Daniel, Controller
  • Dr. Gerrit Los Ph.D., VP of Pharmacology

When did AnaptysBio IPO?

(ANAB) raised $60 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Has AnaptysBio been receiving favorable news coverage?

Media headlines about ANAB stock have trended somewhat positive on Sunday, Accern reports. Accern scores the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AnaptysBio earned a news impact score of 0.13 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 43.79 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are AnaptysBio's major shareholders?

AnaptysBio's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FRAZIER HEALTHCARE V, LP (15.70%), FRAZIER HEALTHCARE V, LP (15.70%), FRAZIER HEALTHCARE V, LP (9.93%), BlackRock Inc. (5.96%), OppenheimerFunds Inc. (4.46%) and Redmile Group LLC (2.23%). Company insiders that own AnaptysBio stock include Healthcare Vii LP Frazier, Holdings A/S Novo, Nicholas Lydon and Ventures Vii L P Avalon. View Institutional Ownership Trends for AnaptysBio.

Which institutional investors are selling AnaptysBio stock?

ANAB stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Franklin Resources Inc., VHCP Management II LLC, Citigroup Inc., BNP Paribas Arbitrage SA, JPMorgan Chase & Co., Spark Investment Management LLC and Candriam Luxembourg S.C.A.. Company insiders that have sold AnaptysBio company stock in the last year include Holdings A/S Novo, Nicholas Lydon and Ventures Vii L P Avalon. View Insider Buying and Selling for AnaptysBio.

Which institutional investors are buying AnaptysBio stock?

ANAB stock was purchased by a variety of institutional investors in the last quarter, including Redmile Group LLC, Millennium Management LLC, Artal Group S.A., Royal Bank of Canada, UBS Group AG, BlackRock Inc., Senzar Asset Management LLC and Guggenheim Capital LLC. Company insiders that have bought AnaptysBio stock in the last two years include Healthcare Vii LP Frazier and Nicholas Lydon. View Insider Buying and Selling for AnaptysBio.

How do I buy shares of AnaptysBio?

Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AnaptysBio's stock price today?

One share of ANAB stock can currently be purchased for approximately $77.90.

How big of a company is AnaptysBio?

AnaptysBio has a market capitalization of $1.83 billion and generates $10 million in revenue each year. The biotechnology company earns $-30,070,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis. AnaptysBio employs 60 workers across the globe.

How can I contact AnaptysBio?

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected]


MarketBeat Community Rating for AnaptysBio (ANAB)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  168 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  275
MarketBeat's community ratings are surveys of what our community members think about AnaptysBio and other stocks. Vote "Outperform" if you believe ANAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANAB will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AnaptysBio (NASDAQ:ANAB) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for AnaptysBio in the last 12 months. Their average twelve-month price target is $138.6250, suggesting that the stock has a possible upside of 77.95%. The high price target for ANAB is $180.00 and the low price target for ANAB is $40.00. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.882.883.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $138.6250$138.6250$124.25$86.1250
Price Target Upside: 77.95% upside53.96% upside1.74% downside21.17% upside

AnaptysBio (NASDAQ:ANAB) Consensus Price Target History

Price Target History for AnaptysBio (NASDAQ:ANAB)

AnaptysBio (NASDAQ:ANAB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2018Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$144.00 ➝ $40.00HighView Rating Details
3/27/2018JMP SecuritiesSet Price TargetBuy$180.00LowView Rating Details
3/27/2018WedbushReiterated RatingOutperform$151.00HighView Rating Details
3/26/2018Stifel NicolausSet Price TargetBuy ➝ Buy$139.00 ➝ $152.00HighView Rating Details
2/19/2018Jefferies GroupBoost Price TargetBuy$6.59 ➝ $145.00HighView Rating Details
2/15/2018SunTrust BanksBoost Price TargetBuy ➝ Buy$115.00 ➝ $162.00LowView Rating Details
1/23/2018Credit Suisse GroupSet Price TargetOutperform ➝ Outperform$85.00 ➝ $135.00MediumView Rating Details
1/19/2018Robert W. BairdReiterated RatingBuy$81.00 ➝ $144.00HighView Rating Details
(Data available from 5/27/2016 forward)

Earnings

AnaptysBio (NASDAQ:ANAB) Earnings History and Estimates Chart

Earnings by Quarter for AnaptysBio (NASDAQ:ANAB)

AnaptysBio (NASDAQ:ANAB) Earnings Estimates

2018 EPS Consensus Estimate: ($2.81)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.46)($0.39)($0.42)
Q2 20183($0.75)($0.69)($0.71)
Q3 20183($0.82)($0.77)($0.79)
Q4 20183($0.90)($0.86)($0.88)

AnaptysBio (NASDAQ ANAB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.4420)($0.63)$1.75 millionViewN/AView Earnings Details
3/5/2018Q4 2017($0.42)($0.30)$0.89 million$3.00 millionViewN/AView Earnings Details
11/7/2017Q3 2017($0.47)($0.45)$2.78 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.4240)($0.13)$3.45 million$7.00 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.1820)($0.75)$1.63 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

AnaptysBio (NASDAQ:ANAB) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

AnaptysBio (NASDAQ ANAB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 20.80%
Insider Trading History for AnaptysBio (NASDAQ:ANAB)
Institutional Ownership by Quarter for AnaptysBio (NASDAQ:ANAB)

AnaptysBio (NASDAQ ANAB) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2018Nicholas LydonDirectorSell33,000$86.88$2,867,040.00301,506View SEC Filing  
8/21/2017Holdings A/S NovoMajor ShareholderSell356,300$21.10$7,517,930.001,936,604View SEC Filing  
8/15/2017Holdings A/S NovoMajor ShareholderSell178,600$21.16$3,779,176.002,436,332View SEC Filing  
8/7/2017Holdings A/S NovoMajor ShareholderSell491,294$21.12$10,376,129.282,952,527View SEC Filing  
8/3/2017Holdings A/S NovoMajor ShareholderSell70,706$23.31$1,648,156.863,009,949View SEC Filing  
7/26/2017Ventures Vii L P AvalonMajor ShareholderSell37,040$24.35$901,924.00View SEC Filing  
1/31/2017Healthcare Vii L.P. FrazierMajor ShareholderBuy400,000$15.00$6,000,000.00View SEC Filing  
1/31/2017Nicholas LydonDirectorBuy16,666$15.00$249,990.00270,957View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AnaptysBio (NASDAQ ANAB) News Headlines

Source:
DateHeadline
Head to Head Review: Supernus Pharmaceuticals (SUPN) and AnaptysBio (ANAB)Head to Head Review: Supernus Pharmaceuticals (SUPN) and AnaptysBio (ANAB)
www.americanbankingnews.com - May 22 at 9:06 AM
 Brokerages Expect AnaptysBio (ANAB) Will Announce Quarterly Sales of $2.53 Million Brokerages Expect AnaptysBio (ANAB) Will Announce Quarterly Sales of $2.53 Million
www.americanbankingnews.com - May 14 at 3:06 AM
Q2 2018 EPS Estimates for AnaptysBio Decreased by Analyst (ANAB)Q2 2018 EPS Estimates for AnaptysBio Decreased by Analyst (ANAB)
www.americanbankingnews.com - May 14 at 2:50 AM
Wedbush Comments on AnaptysBios Q2 2018 Earnings (ANAB)Wedbush Comments on AnaptysBio's Q2 2018 Earnings (ANAB)
www.americanbankingnews.com - May 14 at 2:50 AM
-$0.66 EPS Expected for AnaptysBio (ANAB) This Quarter-$0.66 EPS Expected for AnaptysBio (ANAB) This Quarter
www.americanbankingnews.com - May 12 at 1:29 PM
AnaptysBio (ANAB) Rating Lowered to Sell at Zacks Investment ResearchAnaptysBio (ANAB) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 11 at 5:43 PM
Q2 2018 EPS Estimates for AnaptysBio Reduced by Analyst (ANAB)Q2 2018 EPS Estimates for AnaptysBio Reduced by Analyst (ANAB)
www.americanbankingnews.com - May 11 at 9:30 AM
AnaptysBio Sets the Stage for an Eventful YearAnaptysBio Sets the Stage for an Eventful Year
finance.yahoo.com - May 9 at 4:34 PM
AnaptysBio (ANAB) Announces  Earnings ResultsAnaptysBio (ANAB) Announces Earnings Results
www.americanbankingnews.com - May 8 at 10:30 PM
AnaptysBio Announces First Quarter 2018 Financial Results and Provides Pipeline UpdatesAnaptysBio Announces First Quarter 2018 Financial Results and Provides Pipeline Updates
finance.yahoo.com - May 8 at 4:30 PM
AnaptysBio (ANAB) Given Average Rating of "Buy" by AnalystsAnaptysBio (ANAB) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - May 6 at 1:08 AM
AnaptysBio Announces ANB020 and ANB019 Clinical Data Presentations at the 2018 EAACI CongressAnaptysBio Announces ANB020 and ANB019 Clinical Data Presentations at the 2018 EAACI Congress
finance.yahoo.com - May 1 at 9:25 AM
AnaptysBio (ANAB) Sees Significant Growth in Short InterestAnaptysBio (ANAB) Sees Significant Growth in Short Interest
www.americanbankingnews.com - April 28 at 2:04 AM
 Brokerages Expect AnaptysBio (ANAB) Will Announce Quarterly Sales of $1.83 Million Brokerages Expect AnaptysBio (ANAB) Will Announce Quarterly Sales of $1.83 Million
www.americanbankingnews.com - April 27 at 5:46 AM
 Brokerages Anticipate AnaptysBio (ANAB) Will Announce Earnings of -$0.44 Per Share Brokerages Anticipate AnaptysBio (ANAB) Will Announce Earnings of -$0.44 Per Share
www.americanbankingnews.com - April 25 at 1:20 AM
Noteworthy Friday Option Activity: IONS, ANAB, NVDANoteworthy Friday Option Activity: IONS, ANAB, NVDA
www.nasdaq.com - April 20 at 4:31 PM
Nicholas Lydon Sells 33,000 Shares of AnaptysBio (ANAB) StockNicholas Lydon Sells 33,000 Shares of AnaptysBio (ANAB) Stock
www.americanbankingnews.com - April 18 at 7:15 PM
AnaptysBio (ANAB) Short Interest Up 60.4% in MarchAnaptysBio (ANAB) Short Interest Up 60.4% in March
www.americanbankingnews.com - April 14 at 1:41 AM
AnaptysBio (ANAB) Given Consensus Rating of "Buy" by BrokeragesAnaptysBio (ANAB) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 11 at 1:24 AM
$1.83 Million in Sales Expected for AnaptysBio (ANAB) This Quarter$1.83 Million in Sales Expected for AnaptysBio (ANAB) This Quarter
www.americanbankingnews.com - April 10 at 4:51 AM
AnaptysBio (ANAB) Upgraded to Buy by Zacks Investment ResearchAnaptysBio (ANAB) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - April 10 at 12:01 AM
Zacks: Analysts Expect AnaptysBio (ANAB) to Announce -$0.44 EPSZacks: Analysts Expect AnaptysBio (ANAB) to Announce -$0.44 EPS
www.americanbankingnews.com - April 8 at 1:14 AM
Heres What Pressured AnaptysBio Inc. Again TodayHere's What Pressured AnaptysBio Inc. Again Today
finance.yahoo.com - April 6 at 9:52 AM
Here's What Pressured AnaptysBio Inc. Again TodayHere's What Pressured AnaptysBio Inc. Again Today
finance.yahoo.com - April 6 at 9:52 AM
AnaptysBio (ANAB) Downgraded to "Sector Perform" at Royal Bank of CanadaAnaptysBio (ANAB) Downgraded to "Sector Perform" at Royal Bank of Canada
www.americanbankingnews.com - April 4 at 12:49 PM
Aimmune Still Leads In The Peanut Allergy RaceAimmune Still Leads In The Peanut Allergy Race
seekingalpha.com - April 2 at 4:32 PM
AnaptysBio (ANAB) & Its Competitors Financial ComparisonAnaptysBio (ANAB) & Its Competitors Financial Comparison
www.americanbankingnews.com - April 2 at 1:16 PM
Jefferies Group Begins Coverage on AnaptysBio (ANAB)Jefferies Group Begins Coverage on AnaptysBio (ANAB)
www.americanbankingnews.com - March 31 at 8:16 PM
AnaptysBio Sees Unusually Large Options Volume (ANAB)AnaptysBio Sees Unusually Large Options Volume (ANAB)
www.americanbankingnews.com - March 29 at 6:54 AM
Tread Very Carefully When Investing in AnaptysBio IncTread Very Carefully When Investing in AnaptysBio Inc
investorplace.com - March 28 at 10:54 AM
JMP Securities Analysts Give AnaptysBio (ANAB) a $180.00 Price TargetJMP Securities Analysts Give AnaptysBio (ANAB) a $180.00 Price Target
www.americanbankingnews.com - March 28 at 10:44 AM
Anaptysbio (ANAB) Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy PatientsAnaptysbio (ANAB) Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients
www.streetinsider.com - March 28 at 9:42 AM
Why These Biotechs Diverged On AnaptysBio's Peanut Allergy StudyWhy These Biotechs Diverged On AnaptysBio's Peanut Allergy Study
finance.yahoo.com - March 27 at 4:24 PM
AnaptysBio (ANAB) Given "Outperform" Rating at WedbushAnaptysBio (ANAB) Given "Outperform" Rating at Wedbush
www.americanbankingnews.com - March 27 at 10:07 AM
After-Hours Stock Movers 03/26: (ANAB) (ECR) (RHT) (TSRO) (OSTK) (NVTA) (more...)After-Hours Stock Movers 03/26: (ANAB) (ECR) (RHT) (TSRO) (OSTK) (NVTA) (more...)
www.streetinsider.com - March 27 at 9:51 AM
Stifel Nicolaus Reiterates $152.00 Price Target for AnaptysBio (ANAB)Stifel Nicolaus Reiterates $152.00 Price Target for AnaptysBio (ANAB)
www.americanbankingnews.com - March 27 at 9:43 AM
AnaptysBio (ANAB) Given a $135.00 Price Target at Credit Suisse GroupAnaptysBio (ANAB) Given a $135.00 Price Target at Credit Suisse Group
www.americanbankingnews.com - March 26 at 6:30 PM
BRIEF-Anaptysbio Announces Positive Top-Line Proof-Of-Concept Data For ANB020 In Moderate-To-Severe Baseline Adult Peanut Allergy PatientsBRIEF-Anaptysbio Announces Positive Top-Line Proof-Of-Concept Data For ANB020 In Moderate-To-Severe Baseline Adult Peanut Allergy Patients
www.reuters.com - March 26 at 4:21 PM
AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy PatientsAnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients
finance.yahoo.com - March 26 at 4:21 PM
AnaptysBio (ANAB) Rating Increased to Hold at ValuEngineAnaptysBio (ANAB) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - March 25 at 9:16 PM
Zacks: Analysts Expect AnaptysBio Inc (ANAB) Will Announce Quarterly Sales of $1.83 MillionZacks: Analysts Expect AnaptysBio Inc (ANAB) Will Announce Quarterly Sales of $1.83 Million
www.americanbankingnews.com - March 24 at 8:52 AM
AnaptysBio Inc (ANAB) Expected to Announce Earnings of -$0.44 Per ShareAnaptysBio Inc (ANAB) Expected to Announce Earnings of -$0.44 Per Share
www.americanbankingnews.com - March 22 at 1:18 AM
AnaptysBio Inc (ANAB) Receives Average Recommendation of "Buy" from BrokeragesAnaptysBio Inc (ANAB) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 17 at 1:37 AM
Better Know Biotech: 3 Highfliers That Ought to Be on Your RadarBetter Know Biotech: 3 Highfliers That Ought to Be on Your Radar
finance.yahoo.com - March 15 at 9:19 AM
AnaptysBio (ANAB) and Its Rivals Head to Head ContrastAnaptysBio (ANAB) and Its Rivals Head to Head Contrast
www.americanbankingnews.com - March 8 at 6:00 PM
Wedbush Comments on AnaptysBio Incs Q1 2018 Earnings (ANAB)Wedbush Comments on AnaptysBio Inc's Q1 2018 Earnings (ANAB)
www.americanbankingnews.com - March 8 at 6:40 AM
SunTrust Banks Comments on AnaptysBio Incs Q1 2018 Earnings (ANAB)SunTrust Banks Comments on AnaptysBio Inc's Q1 2018 Earnings (ANAB)
www.americanbankingnews.com - March 8 at 6:40 AM
Jefferies Group Analysts Cut Earnings Estimates for AnaptysBio Inc (ANAB)Jefferies Group Analysts Cut Earnings Estimates for AnaptysBio Inc (ANAB)
www.americanbankingnews.com - March 8 at 6:40 AM
AnaptysBio Gears Up For an Eventful YearAnaptysBio Gears Up For an Eventful Year
finance.yahoo.com - March 6 at 4:50 PM
VHCP Management II LLC Purchases 115,000 Shares of AnaptysBio Inc (ANAB)VHCP Management II LLC Purchases 115,000 Shares of AnaptysBio Inc (ANAB)
www.americanbankingnews.com - March 6 at 10:50 AM

SEC Filings

AnaptysBio (NASDAQ:ANAB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AnaptysBio (NASDAQ:ANAB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AnaptysBio (NASDAQ ANAB) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.